STOCK TITAN

[Form 4] INCYTE CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Incyte (INCY) reported an insider transaction by its EVP & General Counsel. On 10/15/2025, the officer exercised 277 employee stock options at a $64.25 exercise price and sold 277 shares of common stock at $85.13.

Following the transactions, the officer beneficially owned 26,569 shares directly, which includes an aggregate of 25,913 shares issuable from previously reported unvested RSUs and earned performance units. Derivative securities beneficially owned after the transactions totaled 9,161 options. The reported option grant expires on 07/14/2034 and vests in installments as disclosed.

Incyte (INCY) ha riportato una operazione interna da parte del suo EVP e Avvocato Generale. Il 15/10/2025 l ufficiale ha esercitato 277 opzioni azionarie dipendenti al prezzo di esercizio di $64,25 e ha venduto 277 azioni ordinarie al prezzo di $85,13.

A seguito delle operazioni, l ufficiale detiene direttamente in benefici 26.569 azioni, che includono un totale aggregato di 25.913 azioni assegnate da RSU non vestite riportate in precedenza e unità di performance maturate. I titoli derivati posseduti dopo le operazioni ammontavano a 9.161 opzioni. L assegnazione di opzioni riportata scade il 14/07/2034 e vanno vestite in rate come indicato.

Incyte (INCY) reportó una operación interna por parte de su vicepresidente ejecutivo y consejero general. El 15/10/2025, el directivo ejerció 277 opciones de acciones para empleados a un precio de ejercicio de $64.25 y vendió 277 acciones ordinarias a $85.13.

Tras las operaciones, el directivo poseía beneficiosamente directamente 26,569 acciones, lo que incluye un agregado de 25,913 acciones sujetas a RSU no vestidas reportadas previamente y unidades de rendimiento ganadas. Los valores derivados poseídos tras las operaciones totalizaban 9,161 opciones. La adjudicación de la opción reportada vence el 14/07/2034 y se visten en cuotas como se divulgó.

Incyte (INCY)는 최고재무책임자 겸 법무고문이 내부거래를 했다라고 보고했다. 2025년 10월 15일, 그 임원은 277개의 직원 주식 옵션을 행사했고 행사 가격은 $64.25였으며 $85.13의 가격으로 277주의 보통주를 매각했다.

거래 후 임원은 직접적으로 유익하게 26,569주를 보유했고, 여기에는 이전에 보고된 미 vest RSU 및 달성된 성과 단위로부터 발행 가능한 25,913주의 합계가 포함된다. 거래 후 보유한 유도증권은 총 9,161옵션이었다. 보고된 옵션 부여는 2034-07-14에 만료되며, 공시된대로 분할 vesting 된다.

Incyte (INCY) a déclaré une opération interne par son EVP et Directeur général. Le 15/10/2025, le dirigeant a exercé 277 options d'achat d'actions à un prix d'exercice de $64,25 et a vendu 277 actions ordinaires à $85,13.

Suite à ces opérations, le dirigeant détenait directement, pour le compte du bénéficiaire, 26 569 actions, ce qui comprend un total agrégé de 25 913 actions attachées à des RSU non acquises et des unités de performance gagnées. Les instruments dérivés détenus après les opérations s'élevaient à 9 161 options. Le don d'options déclaré arrive à expiration le 14/07/2034 et vest à intervalles comme divulgué.

Incyte (INCY) meldete eine Insider-Transaktion durch seinen EVP & General Counsel. Am 15.10.2025 setzte der Beamte 277 Mitarbeiteraktienoptionen zu einem Ausübungspreis von $64,25 aus und verkaufte 277 Stammaktien zu $85,13.

Nach den Transaktionen hielt der Beamte direkt vorteilhaft 26.569 Aktien, was eine Gesamtsumme von 25.913 Aktien einschließt, die aus zuvor gemeldeten unvesteten RSUs und verdienten Leistungseinheiten stammen. Ableitungswertpapiere, die nach den Transaktionen vorteilhaft besessen wurden, belaufen sich auf 9.161 Optionen. Die gemeldete Optionszuteilung läuft am 14.07.2034 ab und vesting erfolgt wie mitgeteilt in Raten.

إنسيتي (INCY) أبلغت عن صفقة داخلية من قِبَل نائب الرئيس التنفيذي/المستشار العام. في 15/10/2025 نفّذ المسؤول 277 خيار أسهم للموظفين بسعر تنفيذ قدره $64.25 وباع 277 سهماً عادياً بسعر $85.13.

بعد المعاملات، امتلك المسؤول بصفة مستفيد مباشرةً 26,569 سهماً، وهو يشمل إجمالي 25,913 سهماً قابلة الإصدار من RSUs غير vestied والمكوّنات الآداء المحققة. ورقيات مشتقة مملوكة بعد المعاملات بلغ مجموعها 9,161 خياراً. تمنح خيارات العروض المبلغ عنها صلاحيتها في 14/07/2034 وتتم vesting على أقساط كما هو مذكور.

Incyte (INCY) 报告称其执行副总裁兼总法律顾问的内部交易。2025年10月15日,该官员行使了277份员工股票期权, 行使价格为$64.25,并以$85.13的价格出售了277股普通股

交易后,该官员直接受益持有26,569股普通股,其中包括以前报告的未归属RSU和已获得的绩效单位合计25,913股,以及交易后受益的衍生证券合计9,161份期权。所述期权授予的到期日为2034-07-14,并按披露的分期 vesting。

Positive
  • None.
Negative
  • None.

Incyte (INCY) ha riportato una operazione interna da parte del suo EVP e Avvocato Generale. Il 15/10/2025 l ufficiale ha esercitato 277 opzioni azionarie dipendenti al prezzo di esercizio di $64,25 e ha venduto 277 azioni ordinarie al prezzo di $85,13.

A seguito delle operazioni, l ufficiale detiene direttamente in benefici 26.569 azioni, che includono un totale aggregato di 25.913 azioni assegnate da RSU non vestite riportate in precedenza e unità di performance maturate. I titoli derivati posseduti dopo le operazioni ammontavano a 9.161 opzioni. L assegnazione di opzioni riportata scade il 14/07/2034 e vanno vestite in rate come indicato.

Incyte (INCY) reportó una operación interna por parte de su vicepresidente ejecutivo y consejero general. El 15/10/2025, el directivo ejerció 277 opciones de acciones para empleados a un precio de ejercicio de $64.25 y vendió 277 acciones ordinarias a $85.13.

Tras las operaciones, el directivo poseía beneficiosamente directamente 26,569 acciones, lo que incluye un agregado de 25,913 acciones sujetas a RSU no vestidas reportadas previamente y unidades de rendimiento ganadas. Los valores derivados poseídos tras las operaciones totalizaban 9,161 opciones. La adjudicación de la opción reportada vence el 14/07/2034 y se visten en cuotas como se divulgó.

Incyte (INCY)는 최고재무책임자 겸 법무고문이 내부거래를 했다라고 보고했다. 2025년 10월 15일, 그 임원은 277개의 직원 주식 옵션을 행사했고 행사 가격은 $64.25였으며 $85.13의 가격으로 277주의 보통주를 매각했다.

거래 후 임원은 직접적으로 유익하게 26,569주를 보유했고, 여기에는 이전에 보고된 미 vest RSU 및 달성된 성과 단위로부터 발행 가능한 25,913주의 합계가 포함된다. 거래 후 보유한 유도증권은 총 9,161옵션이었다. 보고된 옵션 부여는 2034-07-14에 만료되며, 공시된대로 분할 vesting 된다.

Incyte (INCY) a déclaré une opération interne par son EVP et Directeur général. Le 15/10/2025, le dirigeant a exercé 277 options d'achat d'actions à un prix d'exercice de $64,25 et a vendu 277 actions ordinaires à $85,13.

Suite à ces opérations, le dirigeant détenait directement, pour le compte du bénéficiaire, 26 569 actions, ce qui comprend un total agrégé de 25 913 actions attachées à des RSU non acquises et des unités de performance gagnées. Les instruments dérivés détenus après les opérations s'élevaient à 9 161 options. Le don d'options déclaré arrive à expiration le 14/07/2034 et vest à intervalles comme divulgué.

Incyte (INCY) meldete eine Insider-Transaktion durch seinen EVP & General Counsel. Am 15.10.2025 setzte der Beamte 277 Mitarbeiteraktienoptionen zu einem Ausübungspreis von $64,25 aus und verkaufte 277 Stammaktien zu $85,13.

Nach den Transaktionen hielt der Beamte direkt vorteilhaft 26.569 Aktien, was eine Gesamtsumme von 25.913 Aktien einschließt, die aus zuvor gemeldeten unvesteten RSUs und verdienten Leistungseinheiten stammen. Ableitungswertpapiere, die nach den Transaktionen vorteilhaft besessen wurden, belaufen sich auf 9.161 Optionen. Die gemeldete Optionszuteilung läuft am 14.07.2034 ab und vesting erfolgt wie mitgeteilt in Raten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Denton Sheila A.

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M 277 A $64.25 26,846 D
Common Stock 10/15/2025 S 277 D $85.13 26,569(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $64.25 10/15/2025 M 277 (2) 07/14/2034 Common Stock 277 $0 9,161 D
Explanation of Responses:
1. This includes an aggregate of 25,913 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.
2. The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

17.05B
190.92M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON